What We Do

We discover and develop innovative drug products for treatment of cardiometabolic and other diseases. Using our expertise in amino-lipid chemistry, we transform approved drugs or previously studied, biologically active agents to make them better for patients.

Pipeline

» TP-113 for type 2 diabetes

» TP-252 for familial adenomatous polyposis

» TP-452 for hypercholesterolemia

» TP-8452 for hypercholesterolemia

Learn more about our pipeline. »»

News

June 12, 2015
Thetis Pharmaceuticals to Present at the BIO International Convention on June 16, 2015

April 29, 2015
Thetis Pharmaceuticals Presents Preclinical Data on Novel Oral Agent for Type 2 Diabetes

March 4, 2015
Notice of Allowance on Composition of Matter Patent Expanding Type 2 Diabetes Portfolio

January 19, 2015
Thetis Initiates Diabetes Reversal Study On Metformin-DHA Agent

January 5, 2015
Pharma Industry Veteran Richard Daly Joins Thetis As Commercial Advisor